Wearable Technology: What’s the Role in Early Detection?

Add to iCal Calendar 0

Date(s) - 13 May 2020
12:00 PM - 1:00 PM


Johnson & Johnson Innovation, JLABS (PRNewsFoto/Johnson & Johnson Innovation, LL)

Wearable Technology: What’s the Role in Early Detection?

May 13, 2020

10:00 AM – 12:00 PM PDT/AZ


JLABS Program Overview

When a new infectious disease emerges, health care systems are faced with the challenging task of testing individuals at an increased demand without necessarily having access to the necessary supply of diagnostics. However, as the wearable device market grows and more individuals have the ability to monitor their own health metrics, what role can wearable technologies play in the early disease detection phase?

If wearable devices have the ability to provide continuous sensing capabilities while accurately capturing signals, is there a role that wearable devices play in forecasting illness? What role can wearable technology play in an outbreak response at both the individual level and global level?

Join our panel with industry experts to discuss the potential for innovation in the use of wearable technologies for early detection.

This program is a product of a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.


Julie Schafer, PhD, MPH, Chief Technology Officer, Flu Lab

Julie Schafer, PhD, MPH is the Chief Technology Officer for Flu Lab, seeking to stretch the boundaries of how technology is used toward defeating influenza. Julie has held a number of leadership positions in the US Government, including Chief of Staff, and later Director of Strategy, for the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services (HHS).

Julie served in the White House National Security Council and has led complex influenza vaccine, therapeutic, and diagnostic advanced development programs as well as an initiative toward pre-symptomatic identification of illness and exposures.

Šeila Selimović, PhD, Program Manager in the Biomedical Advanced Research and Development Authority (BARDA)

Šeila Selimović, PhD serves as a Biologist / Program Manager in the Biomedical Advanced Research and Development Authority (BARDA) at the US Department of Health and Human Services. Her work focuses on transformational technologies that provide early and actionable health information to individuals and health care providers.

Prior to BARDA, Šeila was a Program Director at the National Institute of Biomedical Imaging and Bioengineering, and a AAAS Science and Technology Policy Fellow at the US Department of State.

Šeila completed her PhD in Condensed Matter Physics at Brandeis University and pursed a postdoctoral fellowship at Harvard Medical School / Brigham & Women’s Hospital. Her experience includes microfluidics, biosensors, tissue engineering, microphysiological systems, and energy policy.

Jeffrey Bemowski, MBA, CEO of Clairways

Jeffrey Bemowski, MBA, CEO of Clairways, has performed extensive market research to define the customer and unmet need for Clairways technology and to develop partnerships with initial customers.

Jeff previously worked in product management for Endotronix, a digital health company developing hemodynamic monitoring solutions. He also worked as a project management consultant at PwC, advising clients on large technology development programs. And finally, he has experience in finance, where he sized and structured bonds.


1:00pm – Introductions

1:05pm – Panel Presentations

1:30pm – Moderated Q&A

1:45pm – Audience Q&A

2:00pm – Webinar Ends